During the development of a novel therapeutic monoclonal antibody, neutralizumab, designed to treat plaque psoriasis, researchers transition from testing in animal models to clinical trials in humans.
Which of the following describes the primary objective of a Phase II clinical trial for neutralizumab?
To evaluate the safety, tolerability, and metabolic pathways of the antibody in a small group of healthy human volunteers.
To assess the clinical efficacy of the antibody and determine the optimal dosage in a medium-sized cohort of patients suffering from plaque psoriasis.
To compare the therapeutic effectiveness and safety of the antibody against existing standard-of-care treatments in a large, randomised patient population.
To monitor the long-term safety, rare side effects, and real-world performance of the antibody after it has been approved and licensed for general clinical use.
181 exam-style questions on OCR GCSE Biology 6.3 Monitoring and maintaining health, covering 6.3.1 Health and disease, 6.3.2 Interactions between diseases, 6.3.3 Spread of communicable diseases, 6.3.4 Common infections and diseases, 6.3.5 Physical plant defence responses, 6.3.6 Chemical plant defence responses, 6.3.7 Detecting and identifying plant diseases, 6.3.8 White blood cells and platelets, 6.3.9 Non-specific defence systems, 6.3.10 The immune system, 6.3.11 Monoclonal antibodies, 6.3.12 Vaccines and medicines, 6.3.13 Aseptic techniques, 6.3.14 Discovery and development of new medicines, 6.3.15 Causes of non-communicable diseases, 6.3.16 Treatments for cardiovascular disease, 6.3.17 Lifestyle factors and non-communicable diseases, 6.3.18 Cancer, 6.3.19 Stem cells in medicine, 6.3.20 Gene technology in medicine, and 6.3.21 The human genome and medicine. Each one has a worked solution and a mark scheme showing where the marks go.